Cardio Probiotic from Kaneka earns FDA GRAS status
Kaneka Probiotics announced Cardio Probiotic (L. plantarum KABP-011, L. plantarum KABP-012, and L. plantarum KABP-013) achieved U.S. FDA GRAS (Generally Recognized as Safe) status.
Photo © iStockphoto.com/volk65
Kaneka Probiotics (Pasadena, TX) announced Cardio Probiotic (L. plantarum KABP-011, L. plantarum KABP-012, and L. plantarum KABP-013) achieved U.S. FDA GRAS (Generally Recognized as Safe) status.
“The FDA GRAS certification demonstrates our commitment to a higher level of safety and quality for this ingredient,” said Mike Kolifrath, vice president, sales and marketing of the probiotics division at Kaneka, in a press release. “Brands can be assured to have best in class ingredient when selecting to use the Cardio Probiotic raw material blend in their products for lipid metabolism and cardiovascular benefits.”
Cardio Probiotic, based on a foundation of published clinical trials, phenotypic data, and genotypic analysis, is a formulation of three Lactobacillus plantarum strains that specifically supports cholesterol already in normal range.
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
